دورية أكاديمية
أعرض في EDS

Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies.

التفاصيل البيبلوغرافية
العنوان: Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies.
المؤلفون: Popovici D; Department of Oncology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania., Stanisav C; Departments of Radiology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Sima LV; Department of Surgical Semiology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania., Negru A; Department of Cardiology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania., Murg SI; Doctoral School of Medicine, Faculty of Medicine and Pharmacy, University of Oradea, 1 Decembrie Square 10, 410073 Oradea, Romania., Carabineanu A; Department of Surgical Semiology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jun 19; Vol. 60 (6). Date of Electronic Publication: 2024 Jun 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga
مواضيع طبية MeSH: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/pathology , Liver Neoplasms*/secondary , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Fluorouracil*/therapeutic use , Leucovorin*/therapeutic use , Organoplatinum Compounds*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Adult ; Biomarkers, Tumor/blood ; Prognosis ; ErbB Receptors ; Kaplan-Meier Estimate
مستخلص: Background and objectives: Colorectal cancer is a major global health concern, with a significant increase in morbidity and mortality rates associated with metastatic stages. This study investigates the prognostic significance of various clinical and laboratory parameters in patients with metastatic CRC. Materials and Methods: A retrospective cohort of 188 CRC patients with hepatic metastasis from the OncoHelp Association in Timisoara was analyzed from January 2016 to March 2023. Data on demographics, clinical characteristics, and biomarkers, such as lymphocyte counts, as well as various inflammation indices, were examined. Statistical analyses included univariate and multivariate logistic regression, Kaplan-Meier survival analysis, and ROC curve assessments. Results: Our findings indicate significant associations between survival outcomes and several biomarkers. Higher BMI and lymphocyte counts were linked with better survival rates, while higher values of Neutrophil-Hemoglobin-Lymphocyte (NHL) score, Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII) were predictors of poorer outcomes. Notably, the presence of hepatic metastasis at diagnosis was a critical factor, significantly reducing overall survival. Conclusions: The study has expanded the current understanding of prognostic factors in CRC, advocating for a multi-dimensional approach to prognostic evaluations. This approach should consider not only the traditional metrics such as tumor stage and histological grading but also incorporate a broader spectrum of biomarkers. Future studies should aim to validate these findings and explore the integration of these biomarkers into routine clinical practice, enhancing the precision of prognostic assessments and ultimately guiding more personalized treatment strategies for CRC patients.
References: Nutrients. 2023 Apr 06;15(7):. (PMID: 37049633)
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1008-1015. (PMID: 28506965)
Biomark Res. 2021 Jun 5;9(1):44. (PMID: 34090526)
J Cell Mol Med. 2022 Apr;26(7):1918-1931. (PMID: 35122390)
J Inflamm Res. 2023 Jan 07;16:69-81. (PMID: 36643953)
Sci Rep. 2019 Dec 23;9(1):19673. (PMID: 31873162)
Front Med (Lausanne). 2022 Jun 20;9:843074. (PMID: 35795635)
J Clin Lab Anal. 2021 Aug;35(8):e23883. (PMID: 34184796)
Curr Oncol. 2020 Oct;27(5):237-243. (PMID: 33173374)
PLoS One. 2018 Apr 6;13(4):e0195042. (PMID: 29624591)
Nutr Rev. 2023 Jan 10;81(2):233-234. (PMID: 36106797)
J Gastrointest Oncol. 2022 Feb;13(1):197-209. (PMID: 35284113)
Cureus. 2021 Oct 25;13(10):e19025. (PMID: 34722011)
Cancers (Basel). 2022 Mar 11;14(6):. (PMID: 35326592)
Cancer Diagn Progn. 2023 Mar 3;3(2):163-168. (PMID: 36875314)
Rom J Morphol Embryol. 2021 Apr-Jun;62(2):605-613. (PMID: 35024752)
BMC Cancer. 2017 Dec 06;17(1):827. (PMID: 29207960)
Br J Cancer. 2021 Jul;125(1):119-125. (PMID: 33875823)
Acta Oncol. 2018 Nov;57(11):1438-1444. (PMID: 30035653)
Trends Pharmacol Sci. 2023 Apr;44(4):222-236. (PMID: 36828759)
J Oncol. 2019 Sep 19;2019:7407190. (PMID: 31641356)
Medicine (Baltimore). 2023 Mar 17;102(11):e33279. (PMID: 36930098)
Ann Oncol. 2020 Oct;31(10):1291-1305. (PMID: 32702383)
J Clin Med. 2023 Oct 15;12(20):. (PMID: 37892677)
J Cancer. 2023 Jan 22;14(3):322-335. (PMID: 36860923)
BMC Cancer. 2018 Sep 20;18(1):906. (PMID: 30236083)
J Clin Oncol. 2023 Jan 20;41(3):678-700. (PMID: 36252154)
Cancer Med. 2021 Sep;10(17):5983-5997. (PMID: 34308567)
Medicina (Kaunas). 2023 Jan 06;59(1):. (PMID: 36676741)
فهرسة مساهمة: Keywords: Body Mass Index (BMI); NHL score; NLR; PLR; ROC curve; SII; biomarkers; colorectal cancer; lymphocytes; patient demographics; survival analysis
المشرفين على المادة: U3P01618RT (Fluorouracil)
Q573I9DVLP (Leucovorin)
0 (Organoplatinum Compounds)
XT3Z54Z28A (Camptothecin)
0 (Biomarkers, Tumor)
EC 2.7.10.1 (ErbB Receptors)
SCR Protocol: IFL protocol; Folfox protocol
تواريخ الأحداث: Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11205545
DOI: 10.3390/medicina60061003
PMID: 38929620
قاعدة البيانات: MEDLINE
الوصف
تدمد:1648-9144
DOI:10.3390/medicina60061003